ADIPOQ and Abdominal obesity: Even if growing evidence supports that obesity leads to an increased inflammation and fibrosis together with a decreased expression levels of the anti-inflammatory adiponectin also in the subcutaneous adipose tissue (8), visceral fat accumulation (the so-called “abdominal obesity” or “central obesity”), is usually more markedly characterized by an impaired profile of adipokines, with increased proinflammatory signals (9).